Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**poria + gamma-aminobutyric acid** is an oral multi-ingredient dietary supplement that combines extracts of *Poria cocos* (a fungus used in traditional medicine) with gamma-aminobutyric acid (GABA), the key inhibitory neurotransmitter in the mammalian central nervous system. It is typically developed as part of integrative or functional medicine approaches for improving sleep quality and, potentially, skin health. Randomized controlled trials indicate that combinations containing Poria cocos, GABA, and other botanicals can lead to clinically significant improvements in sleep parameters and skin hydration, without reported adverse effects. The purported mechanism is the synergistic anxiolytic and sleep-promoting effect, attributed both to GABAergic activity (via GABA receptors in the CNS) and possible adaptogenic or sedative effects from *Poria cocos*. These products are generally categorized as dietary supplements rather than pharmaceuticals and are not approved for treatment or prevention of disease but may be marketed for wellness benefits and sleep support[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on poria + gamma-aminobutyric acid.